Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley and Gerburg M. Wulf
Ashish Juvekar
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura N. Burga
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hai Hu
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaine P. Lunsford
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasir H. Ibrahim
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Balmañà
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anbazhagan Rajendran
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonella Papa
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Spencer
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Costas A. Lyssiotis
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caterina Nardella
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Paolo Pandolfi
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Baselga
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Scully
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Asara
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lewis C. Cantley
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerburg M. Wulf
Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-11-0336 Published November 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2012 to January 2021

AbstractFull-text HTMLPDF
Total121131088621549

Cited By

Article Information

Volume 2, Issue 11, pp. 1048-1063

DOI 
https://doi.org/10.1158/2159-8290.CD-11-0336
PubMed 
22915751

Published By 
American Association for Cancer Research
Print ISSN 
2159-8274
Online ISSN 
2159-8290
History 
  • Received December 21, 2011
  • Revision received July 1, 2012
  • Accepted August 8, 2012
  • Published first August 22, 2012.

Article Versions

  • Previous version (August 22, 2012 - 05:26).
  • Previous version (October 2, 2012 - 07:43).
  • Previous version (October 23, 2012 - 13:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2012 American Association for Cancer Research.

Author Information

  1. Ashish Juvekar1,
  2. Laura N. Burga1,
  3. Hai Hu1,
  4. Elaine P. Lunsford1,
  5. Yasir H. Ibrahim5,
  6. Judith Balmañà5,
  7. Anbazhagan Rajendran1,
  8. Antonella Papa2,
  9. Katherine Spencer1,
  10. Costas A. Lyssiotis3,
  11. Caterina Nardella2,
  12. Pier Paolo Pandolfi2,
  13. José Baselga4,5,
  14. Ralph Scully1,
  15. John M. Asara3,
  16. Lewis C. Cantley3 and
  17. Gerburg M. Wulf1
  1. Authors' Affiliations: Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
  1. Corresponding Author:
    Gerburg M. Wulf, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-667-1910; Fax: 617-667-1960; E-mail: gwulf{at}bidmc.harvard.edu
  1. L.N. Burga and H. Hu contributed equally to this work.

View Full Text
PreviousNext
Back to top
Cancer Discovery: 2 (11)
November 2012
Volume 2, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley and Gerburg M. Wulf
Cancer Discov November 1 2012 (2) (11) 1048-1063; DOI: 10.1158/2159-8290.CD-11-0336

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley and Gerburg M. Wulf
Cancer Discov November 1 2012 (2) (11) 1048-1063; DOI: 10.1158/2159-8290.CD-11-0336
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Methods
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • YTHDF2 Maintains Glioblastoma Stem Cells
  • Genomic Profiling in FGFR2-Rearranged Cholangiocarcinoma
  • Organoid Platform for Developing Ovarian Cancer Therapies
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement